Crs Bioengineering Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 31-05-2024
- Paid Up Capital ₹ 0.10 M
as on 31-05-2024
- Company Age 11 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2017)
- Profit -19.66%
(FY 2017)
- Ebitda
- Net Worth -9.87%
(FY 2017)
- Total Assets -0.84%
(FY 2017)
About Crs Bioengineering
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Vineethwel Prem and Prem Samuel serve as directors at the Company.
- CIN/LLPIN
U24100TN2012PTC088767
- Company No.
088767
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Dec 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Kanchipuram, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Crs Bioengineering Private Limited offer?
Crs Bioengineering Private Limited offers a wide range of products and services, including Extraction Plants and Extruders, Extraction Machinery, Fresh Flowers, Plants & Trees, Garden Plant, Fruit & Vegetable Processor, Fruit Processing Plant, Pharmaceutical Machinery & Equipment, Pharmaceutical Machines, Pharmaceutical Processing Plant, Agro Farming Services.
Who are the key members and board of directors at Crs Bioengineering?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Vineethwel Prem | Director | 02-Dec-2022 | Current |
Prem Samuel  | Director | 03-Dec-2012 | Current |
Financial Performance and Corporate Structure Insights of Crs Bioengineering.
Crs Bioengineering Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 19.66% decrease in profit. The company's net worth dipped by a decrease of 9.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Crs Bioengineering?
In 2017, Crs Bioengineering had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
1 year 11 months Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Crs Bioengineering?
Unlock and access historical data on people associated with Crs Bioengineering, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Crs Bioengineering, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Crs Bioengineering's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
